;M&A, Licensing and Commercial TransactionsKey legal issues shaping life sciences and health care M&ARead moreEfforts obligations: Looking beyond the definition in life sciences collaborationsRead moreThe benefits of arbitrating life sciences disputesRead moreNew M&A playbook for AI‑enabled devicesRead moreNavigating contractual issues arising from clinical trialsRead moreStandard contractual clauses for Clinical Trial Agreements in Germany: What sponsors need to knowRead moreCross-border licensing-to-acquire structures: A new page in the M&A playbook in a constrained deal marketRead moreRegulatory-risk arbitrage M&A: Navigating transactions amid divergent regulatory requirementsRead moreFinancialization of private practice companies in France: Effective control as a governance standardRead moreThe rise of "NewCo" models in China: Legal structures for cross-border pharma partnershipsRead moreChina's drug regulatory data protection rules: Implications for licensing transactionsRead moreJapan 2026: Life sciences transactions shift from caution to catalystRead morePrevious pageNext page
